Cingulate Net Income

CING Stock  USD 6.49  0.24  3.84%   
As of the 5th of February, Cingulate shows the Downside Deviation of 5.07, mean deviation of 3.3, and Risk Adjusted Performance of 0.1573. Cingulate technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Cingulate jensen alpha, as well as the relationship between the potential upside and skewness to decide if Cingulate is priced correctly, providing market reflects its regular price of 6.49 per share. Given that Cingulate has jensen alpha of 0.8677, we suggest you to validate Cingulate's prevailing market performance to make sure the company can sustain itself at a future point.
Cingulate's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Cingulate's valuation are provided below:
Gross Profit
-12.1 M
Market Capitalization
46.4 M
Earnings Share
(2.77)
There are over one hundred nineteen available fundamental signals for Cingulate, which can be analyzed over time and compared to other ratios. Active traders should verify all of Cingulate prevailing fundamental drivers against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
Last ReportedProjected for Next Year
Net Loss-14 M-14.7 M
Net Loss-15.9 M-16.7 M
Net Loss-14 M-14.7 M
Net Loss(3.67)(3.85)
Net Income Per E B T 0.90  0.80 
The current Net Loss is estimated to decrease to about (14.7 M). The current Net Loss is estimated to decrease to about (16.7 M).
  
Build AI portfolio with Cingulate Stock
The Net Income trend for Cingulate offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Cingulate is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.

Latest Cingulate's Net Income Growth Pattern

Below is the plot of the Net Income of Cingulate over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Cingulate financial statement analysis. It represents the amount of money remaining after all of Cingulate operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Cingulate's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cingulate's overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (15.55 M)10 Years Trend
Slightly volatile
   Net Income   
       Timeline  

Cingulate Net Income Regression Statistics

Arithmetic Mean(13,470,582)
Coefficient Of Variation(29.69)
Mean Deviation3,003,506
Median(11,546,298)
Standard Deviation3,999,571
Sample Variance16T
Range16.4M
R-Value(0.53)
Mean Square Error12.3T
R-Squared0.28
Significance0.03
Slope(417,359)
Total Sum of Squares255.9T

Cingulate Net Income History

2026-14.7 M
2025-14 M
2024-15.5 M
2023-23.5 M
2022-17.9 M
2021-20.7 M
2020-7.2 M

Other Fundumenentals of Cingulate

Cingulate Net Income component correlations

Cingulate Net Income Driver Correlations

Understanding the fundamental principles of building solid financial models for Cingulate is extremely important. It helps to project a fair market value of Cingulate Stock properly, considering its historical fundamentals such as Net Income. Since Cingulate's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cingulate's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cingulate's interrelated accounts and indicators.
Can Biotechnology industry sustain growth momentum? Does Cingulate have expansion opportunities? Factors like these will boost the valuation of Cingulate. Projected growth potential of Cingulate fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cingulate demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(2.77)
Return On Assets
(1.07)
Return On Equity
(2.76)
Understanding Cingulate requires distinguishing between market price and book value, where the latter reflects Cingulate's accounting equity. The concept of intrinsic value - what Cingulate's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cingulate's price substantially above or below its fundamental value.
It's important to distinguish between Cingulate's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cingulate should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cingulate's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.

Cingulate 'What if' Analysis

In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Cingulate's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Cingulate.
0.00
11/07/2025
No Change 0.00  0.0 
In 3 months and 1 day
02/05/2026
0.00
If you would invest  0.00  in Cingulate on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding Cingulate or generate 0.0% return on investment in Cingulate over 90 days. Cingulate is related to or competes with Allarity Therapeutics, Lexaria Bioscience, Lixte Biotechnology, Kairos Pharma, Synlogic, CASI Pharmaceuticals, and Entero Therapeutics. Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the tre... More

Cingulate Upside/Downside Indicators

Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Cingulate's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Cingulate upside and downside potential and time the market with a certain degree of confidence.

Cingulate Market Risk Indicators

Today, many novice investors tend to focus exclusively on investment returns with little concern for Cingulate's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Cingulate's standard deviation. In reality, there are many statistical measures that can use Cingulate historical prices to predict the future Cingulate's volatility.
Hype
Prediction
LowEstimatedHigh
2.527.3012.08
Details
Intrinsic
Valuation
LowRealHigh
7.0211.8016.58
Details
Naive
Forecast
LowNextHigh
1.986.7611.54
Details
4 Analysts
Consensus
LowTargetHigh
24.0926.4829.39
Details

Cingulate February 5, 2026 Technical Indicators

Cingulate Backtested Returns

Cingulate appears to be somewhat reliable, given 3 months investment horizon. Cingulate secures Sharpe Ratio (or Efficiency) of 0.2, which signifies that the company had a 0.2 % return per unit of risk over the last 3 months. By analyzing Cingulate's technical indicators, you can evaluate if the expected return of 0.98% is justified by implied risk. Please makes use of Cingulate's Mean Deviation of 3.3, downside deviation of 5.07, and Risk Adjusted Performance of 0.1573 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Cingulate holds a performance score of 16. The firm shows a Beta (market volatility) of 1.16, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Cingulate will likely underperform. Please check Cingulate's sortino ratio, skewness, period momentum indicator, as well as the relationship between the potential upside and rate of daily change , to make a quick decision on whether Cingulate's price patterns will revert.

Auto-correlation

    
  0.74  

Good predictability

Cingulate has good predictability. Overlapping area represents the amount of predictability between Cingulate time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Cingulate price movement. The serial correlation of 0.74 indicates that around 74.0% of current Cingulate price fluctuation can be explain by its past prices.
Correlation Coefficient0.74
Spearman Rank Test0.74
Residual Average0.0
Price Variance0.53
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Competition

Cingulate Accumulated Other Comprehensive Income

Accumulated Other Comprehensive Income

132.74

At this time, Cingulate's Accumulated Other Comprehensive Income is most likely to increase significantly in the upcoming years.
Based on the recorded statements, Cingulate reported net income of (15.55 Million). This is 104.56% lower than that of the Biotechnology sector and 122.19% lower than that of the Health Care industry. The net income for all United States stocks is 102.72% higher than that of the company.

Cingulate Net Income Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cingulate's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cingulate could also be used in its relative valuation, which is a method of valuing Cingulate by comparing valuation metrics of similar companies.
Cingulate is currently under evaluation in net income category among its peers.

Cingulate ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Cingulate's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Cingulate's managers, analysts, and investors.
Environmental
Governance
Social

Cingulate Institutional Holders

Institutional Holdings refers to the ownership stake in Cingulate that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Cingulate's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Cingulate's value.
Shares
Sbi Securities Co Ltd2025-06-30
251
Advisor Group Holdings, Inc.2025-06-30
42.0
Commonwealth Equity Services Inc2025-06-30
120.5 K
Vanguard Group Inc2025-06-30
35.4 K
Susquehanna International Group, Llp2025-06-30
33.2 K
Geode Capital Management, Llc2025-06-30
32.2 K
Virtu Financial Llc2025-06-30
13.4 K
Ubs Group Ag2025-06-30
12.6 K
Lpl Financial Corp2025-06-30
12.2 K
Xtx Topco Ltd2025-06-30
10.9 K
Bank Of America Corp2025-06-30
7.5 K

Cingulate Fundamentals

About Cingulate Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cingulate's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cingulate using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cingulate based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

When determining whether Cingulate is a strong investment it is important to analyze Cingulate's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cingulate's future performance. For an informed investment choice regarding Cingulate Stock, refer to the following important reports:
Check out
For more detail on how to invest in Cingulate Stock please use our How to Invest in Cingulate guide.
You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Can Biotechnology industry sustain growth momentum? Does Cingulate have expansion opportunities? Factors like these will boost the valuation of Cingulate. Projected growth potential of Cingulate fundamentally drives upward valuation adjustments. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating Cingulate demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
Earnings Share
(2.77)
Return On Assets
(1.07)
Return On Equity
(2.76)
Understanding Cingulate requires distinguishing between market price and book value, where the latter reflects Cingulate's accounting equity. The concept of intrinsic value - what Cingulate's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Market sentiment, economic cycles, and investor behavior can push Cingulate's price substantially above or below its fundamental value.
It's important to distinguish between Cingulate's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cingulate should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Cingulate's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.